We also examined CD44, a well-established biomarker for PNET in children[28] and with prognostic value[29], which is involved in the activation of MMP9 [30], and is targeted by miR-520c and miR-373 by suppressing CD44 translation [26,31]. This evidence concerns the gene CD44 and primitive neuroectodermal tumor.